FDA's CBD Docket Comments: Harm Reduction To Churches, 'More Humane' Medication To 'Source Of Confusion'
Consumers' submissions, many with anonymous attribution, account for most of the 776 comments FDA has received to its "Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds" docket. Few provide data or other information FDA asks for and some organizations' comments align with consumers by focusing on sentiment and appreciation.
You may also be interested in...
US Wellness Market In 2019: Farm Bill Made Cultivating Cannabidiol Policy FDA's Main Course In Supplements
As HBW Insight looks back on notable US wellness market developments and events for the previous 12 months, we find that news in the CBD space from the FDA and the industry dominated the sector throughout 2019.
White House, Democrat majority in Congress and likely next FTC chair support the agency wielding the authority, says advertising law attorney Holly Melton. Supreme Court, though, likely will rule in pending cases that a strict reading of an FTC regulation doesn’t grant monetary penalty authority.
Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.